Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$1.45M$1.45M+47.4% vs Q3 2019 Net Income-$10.66M-$10.66MN/M vs Q3 2019 EPS Diluted-$0.25-$0.25N/M vs Q3 2019 Operating Income-$10,465,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,454,000N/M Margins · derivedOperating margin-722.2%+1603.7 pt vs Q3 2019
Net margin-735.6%+4892.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 4, 2020 · 35 d after period end